As I understand it, We are conducting an open-labe
Post# of 157598

YES open-label trials can be amended which is common such as patient assessments, schedules inclusion/exclusion criteria or for that matter the study's objectives
Both the IRB and Cytodyn must sign off. The patients must sign the amendments.
PD-L1 expressions would also come into play in the Whack-a-mole division.

